Inebilizumab-cdon, a monoclonal antibody that depletes B cells, reduces the risk for flares without showing any new safety signals in patients with immunoglobulin G4-related disease (IgG4-RD) who ...

In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of attacks over a mean 19 months of treatment, according to research ...

The inebilizumab arm also saw a greater change from baseline in QMG score compared with placebo at 52 weeks (adjusted difference, -4.3 [95% CI, -5.9, -2.8]; ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease ...

-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous ...

Findings showed treatment with inebilizumab significantly reduced the risk of IgG4-RD flare by 87% compared with placebo. In patients with immunoglobulin G4-related disease (IgG4-RD), treatment ...

Inebilizumab also depletes B cells, though by binding to the CD19 antigen versus rituximab's CD20 target, and Stone's group (backed by the drug's manufacturer, Amgen) ...

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-Momentum): a double-blind randomized placebo-controlled 2/3 trial [published online September 5, 2019].

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, including plasmablasts and some plasma cells, that are integral to the ...

Among individuals who were prescribed approved biologics for neuromyelitis optica spectrum disorder, those on inebilizumab had significantly higher medication adherence, according to a study ...

UPLIZNA ® (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients ...